Myelodysplastic Syndromes (MDS)

Empowering Oncology Providers: Digital Guide to Cancer Care. Learn more >

podcasts
modules
This site is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

podcasts

Zachariah DeFilipp, MD

Zachariah DeFilipp, MD

Dr. DeFilipp is Director of Bone Marrow Transplant Clinical Research at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. Dr. DeFilipp received his medical degree from Tel Aviv University's Sackler School of Medicine in 2010... Read more >

Elizabeth Griffiths , MD

Elizabeth Griffiths , MD

Dr. Griffiths is Director of the Myelodysplastic Syndromes (MDS) program at Roswell Park Comprehensive Cancer Center, recognized by The MDS Foundation as an MDS Center of Excellence. She is also an Associate Professor of Medicine at the State University of New York at Buffalo... Read more >

Courtney DiNardo, MD MSCE

Courtney DiNardo, MD MSCE

Dr. DiNardo is an Associate Professor of Medicine and Clinical Researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas. Her research focuses on prognostication and personalized therapeutics for patients with myeloid malignancies. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials... Read more >

Explore more of our podcast episodes across these platforms:

modules

Fast Facts: Myelodysplastic Syndromes

open course
Taiho - Logo

transparency statement

This site is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

Copyright © 2023 Oncology Learning Hub. All rights reserved.
Top
Courtney DiNardo, MD MSCE

Courtney DiNardo, MD MSCE

Dr. DiNardo is an Associate Professor of Medicine and Clinical Researcher at The University of Texas MD Anderson Cancer Center in Houston, Texas. Her research focuses on prognostication and personalized therapeutics for patients with myeloid malignancies. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients. In addition, Dr. DiNardo’s clinical and research focus pertaining to hereditary cancer predisposition syndromes has led to the development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which now provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.

Elizabeth Griffiths , MD

Elizabeth Griffiths, MD

Dr. Griffiths is Director of the Myelodysplastic Syndromes (MDS) program at Roswell Park Comprehensive Cancer Center, recognized by The MDS Foundation as an MDS Center of Excellence. She is also an Associate Professor of Medicine at the State University of New York at Buffalo, and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics, Translational Medicine and Immunology. Her research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. Dr. Griffiths and her team have examined how HMAs can cause re-expression of proteins in cancer cells that can be targeted by the immune system. She has authored/co-authored more than 50 peer-reviewed publications, and has been recognizes as on of the “Top Doctors of 2023” by Buffalo Spree magazine.

Zachariah DeFilipp, MD

Zachariah DeFilipp, MD

Dr. DeFilipp is Director of Bone Marrow Transplant Clinical Research at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. Dr. DeFilipp received his medical degree from Tel Aviv University's Sackler School of Medicine in 2010. Following his internship and residency in internal medicine at the Western Pennsylvania Allegheny Health System in Pittsburgh, PA, he completed his fellowship in hematology and medical oncology at the Winship Cancer Institute of Emory University in Atlanta, GA. In 2016, Dr. DeFilipp joined the Blood and Marrow Transplant Program at the Massachusetts General Hospital Cancer Center. Dr. DeFilipp is actively involved in translational and clinical research initiatives to improve outcomes for patients undergoing autologous and allogeneic hematopoietic cell transplantation. He serves as principal investigator on multiple clinical trials for the Blood and Marrow Transplant Program at Massachusetts General Hospital.

Ben George

Ben George, MD

Dr. George is a gastrointestinal medical oncologist and Associate Professor of Medicine at the Medical College of Wisconsin. His practice has entirely consisted of gastrointestinal malignancies for over a decade. He is also Medical Director of the clinical trials office at the Medical College of Wisconsin, where his research focuses on novel biomarkers and novel treatments for gastrointestinal cancers. Dr. George has been involved with several trials that have advanced the treatment of gastrointestinal cancers, and he is passionate about continuing to push for advancements in cancer care.

Reetu Mukherij

Reetu Mukherji, MD

Dr. Mukherji is a gastrointestinal medical oncologist and Assistant Professor of Medicine at MedStar Georgetown University Hospital. She also leads the medical oncology department’s clinical and research focus on upper gastrointestinal malignancies, including esophageal and gastric cancers, at the Georgetown Lombardi Comprehensive Cancer Center. In her clinical work, she primarily cares for patients with gastrointestinal cancers. Dr. Mukherji’s research interests are in patients with gastrointestinal tumors—looking at novel therapeutics and novel biomarkers. Dr. Mukherji strongly believes in the value of working collaboratively with patients, their support systems, and multi-disciplinary teams to deliver the highest level of care and support through their cancer diagnosis.

Arvind Dasari

Arvind Dasari, MD MS

Dr. Dasari is a medical oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is co-Chair of the MD Anderson multidisciplinary neuroendocrine tumor board and his clinical focus is on neuroendocrine malignancies. Dr. Dasari’s research interests include clinical, translational and outcomes work in gastrointestinal cancers. He is currently a member of the NCI Task Force for Neuroendocrine Tumors, is co-Chair of the SWOG Neuroendocrine Subcommittee and also chairs the NANETS’ Continuing Education Committee. Dr. Dasari is passionate about the advancement of treatment options for patients with cancer.

Melinda Bachini

Melinda Bachini

Melinda Bachini is a 13-year survivor of cholangiocarcinoma. In 2012 she was treated at the National Cancer Institute by Dr. Rosenberg in a clinical trial using Adoptive Cell Therapy with TIL. Due to an exceptional and breakthrough response to this treatment, her story was published in the New York Times and other media.

Marina Baretti, MD

Marina Baretti, MD

Dr. Marina Baretti is an Assistant Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, USA. Dr. Baretti completed medical school at the University of Pisa, Italy, and she continued her medical training in Internal Medicine and Oncology at the University of Milan.

Sameek Roychowdhury, MD PhD

Sameek Roychowdhury, MD PhD

Dr. Sameek Roychowdhury received his M.D. at The Ohio State University. He completed his Ph.D. dissertation research with his mentor Michael Caligiuri, M.D., studying cancer immunology and experimental therapeutics. He completed his internal medicine and medical oncology fellowship training at University of Michigan.

Taiho - Logo